Journal article
On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective
Abstract
Cost containment in pharmaceutical-benefit plans are often controversially debated for their potential of unintended consequences on health and overall expenditures. Thorough evaluations are needed but hypotheses and design considerations are complex. Our objective is to provide a structured framework for the evaluation of drug-benefit changes using longitudinal claims data. Differential cost sharing (DCS) will serve as a recent example. …
Authors
Schneeweiss S; Maclure M; Walker AM; Grootendorst P; Soumerai SB
Journal
Health Policy, Vol. 55, No. 2, pp. 97–109
Publisher
Elsevier
Publication Date
2 2001
DOI
10.1016/s0168-8510(00)00120-2
ISSN
0168-8510